Managing Atopic Dermatitis in Nail Technicians
The FDA monitors but does not regulate the use of nail products containing potentially harmful ingredients that are considered safe when used as directed.
Dermatitis
DERMATITIS
FEATURE ARTICLE
LATEST NEWS
Atopic Dermatitis Associated With Heterogeneous Lesion Distribution, Distinct Phenotypes
Atopic dermatitis is associated with a heterogeneous distribution of lesions and several distinct patterns of lesional distribution, which were associated with poorer quality of life.
Variable Patch Test Results in Patients With Atopic Dermatitis Receiving Dupilumab
Investigators sought to determine the effect dupilumab has on patch testing results and improvement of allergic contact dermatitis in patients with allergic dermatitis.
Enhancing Placebo-Controlled Trials for Systemic Atopic Dermatitis Therapy
A group of councilors and associates of the International Eczema Council provide practice recommendations for the design and execution of placebo-controlled-trials with systemic medications for atopic dermatitis.
Dupilumab and Conjunctivitis Strongly Linked in Atopic Dermatitis Trials
Investigators observed that conjunctivitis is more common with dupilumab treatment in clinical trials of patients with atopic dermatitis than trials in patients with asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic esophagitis.
Mothers of Children With Eczema More Likely to Have Exhaustion
For all measures, worse child atopic dermatitis severity linked to worse maternal sleep outcomes
Increased Frequency of Eosinophilia Examined With Dupilumab in Patients With Atopic Dermatitis
Dupilumab demonstrated similar efficacy to that seen in clinical trials, but higher rates of conjunctivitis and eosinophilia.
Two Phase 1 Studies Evaluate Safety of Tezepelumab for Atopic Dermatitis
Two phase 1 studies assessed the safety, tolerability, and pharmacokinetics of tezepelumab with evidence of efficacy in asthma and potential therapeutic benefit in atopic dermatitis.
Disease Severity in Pediatric Atopic Dermatitis Linked to Nasal, Skin Microbiome
The study showed that both the nasal and skin microbiomes are associated with the severity of atopic dermatitis in children.
Dupilumab Decreases Disease Severity and Extent of Atopic Dermatitis
Data from 4 phase 3 trials suggest that all anatomic regions are equally responsive to dupilumab treatment in patients with moderate-to-severe atopic dermatitis.
Dupixent Approved to Treat Adolescent Patients With Moderate-to-Severe Atopic Dermatitis
The FDA has approved the use of Dupixent (dupilumab; Sanofi and Regeneron) to treat moderate-to-severe atopic dermatitis in adolescent patients 12–17 years old.
Want to read more?
Please login or register first to view this content.
Next post in Dermatitis
